FDA Approves DIFFERIN EPIDUO — Galderma Laboratories, L.P.

NDA220736 cleared by FDA on June 22, 2026 for its proprietary brand, NDA220736, which received FDA clearance on June 22, 2026, offering Galderma Laboratories a strategic dual-action topical treatment for acne. This regulatory milestone expands the company's dermatological portfolio and enhances its market position by combining adapalene and benzoyl peroxide into a single, differentiated solution.